You are here

Lancet Neurol DOI:10.1016/S1474-4422(19)30403-X

Towards a treatment for genetic prion disease: trials and biomarkers.

Publication TypeJournal Article
Year of Publication2020
AuthorsVallabh, SM, Minikel, EVallabh, Schreiber, SL, Lander, ES
JournalLancet Neurol
Volume19
Issue4
Pages361-368
Date Published2020 Apr
ISSN1474-4465
Abstract

Prion disease is a rare, fatal, and exceptionally rapid neurodegenerative disease. Although incurable, prion disease follows a clear pathogenic mechanism, in which a single gene gives rise to a single prion protein (PrP) capable of converting into the sole causal disease agent, the misfolded prion. As efforts progress to leverage this mechanistic knowledge toward rational therapies, a principal challenge will be the design of clinical trials. Previous trials in prion disease have been done in symptomatic patients who are often profoundly debilitated at enrolment. About 15% of prion disease cases are genetic, creating an opportunity for early therapeutic intervention to delay or prevent disease. Highly variable age of onset and absence of established prodromal biomarkers might render infeasible existing models for testing drugs before disease onset. Advancement of near-term targeted therapeutics could crucially depend on thoughtful design of rigorous presymptomatic trials.

DOI10.1016/S1474-4422(19)30403-X
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/32199098?dopt=Abstract

Alternate JournalLancet Neurol
PubMed ID32199098
Additional Materials